Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "clinical trials"

NewsRSS3 days ago

Test Your Knowledge About Clinical Trials for HDFN

This article invites people to take a quiz about clinical trials for HDFN (hemolytic disease of the fetus and newborn), which is a serious blood condition that affects unborn babies and newborns. After completing the quiz, you can see how your answers compare to other people who took it. The article doesn't provide new trial information, but rather encourages learning about existing trials through an interactive quiz.

WHY IT MATTERSTaking this quiz helps patients and caregivers understand what clinical trials are available for HDFN, which is important since treatment options and trial availability can directly affect care decisions for affected pregnancies and newborns.
Good to knowHemolytic disease of the fetus and newbornRead →
Clinical trialRSS3 days ago

AAN 2026: Switch to Vyalev stops troublesome dyskinesia in trial

A new medication called Vyalev helped people with Parkinson's disease stop experiencing unwanted, uncontrolled movements (called dyskinesia) when they switched to it from other Parkinson's drugs. In two clinical trials, most people saw these troublesome movements go away within a few months of starting Vyalev. This is good news because dyskinesia is a common side effect that happens after taking Parkinson's medications for a long time.

WHY IT MATTERSIf you have Parkinson's disease and experience dyskinesia from your current levodopa treatment, switching to Vyalev could eliminate these involuntary movements within months rather than managing them as a permanent side effect.
💬 Ask your doctorParkinson's diseaseRead →
AdvocacyRSS3 days ago

Collaboration aims to improve design of FSHD clinical trials

Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.

WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
Good to knowFacioscapulohumeral muscular dystrophyRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases